Md Yuzaiful Md Yusof1, Edward M Vital1, Sudipto Das1, Shouvik Dass1, Gururaj Arumugakani2, Sinisa Savic3, Andrew C Rawstron4, Paul Emery1. 1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 3. NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 4. Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Abstract
OBJECTIVE: To assess clinical and B cell biomarkers to predict relapse after rituximab in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) using retreatment on clinical relapse strategy. METHODS: 35 patients with AAV received treatment with 2×1000 mg rituximab, repeated on clinical relapse (up to 5 cycles). Disease activity was assessed by Birmingham Vasculitis Activity Score (BVAS) and peripheral B cell subsets using highly sensitive flow cytometry (HSFC) as previously described; both performed at baseline and every 3 months. RESULTS: Response rates were high: >83%, with median time-to-relapse of 82 weeks for cycle 1 (C1) and >54 weeks for all cycles. Prior to rituximab, AAV was characterised by naïve B-lymphopenia compared to healthy controls. This dysregulation was more marked in patients with raised C-reactive protein (CRP) (p<0.05). In C1, no clinical feature predicted relapse. However, repopulation of naïve B cell at 6 months was associated with a reduced risk of relapse (HR: 0.326, 95% 0.114 to 0.930, p=0.036). Relapse rates at 12 and 18 months were 0% and 14% with naïve repopulation at 6 months, and 31% and 54% without naïve repopulation. CONCLUSIONS: Responses to B cell depletion therapy are long-lasting and relapse post-treatment may be predicted by absence of naïve B cell repopulation at 6 months. Naïve B-lymphopenia may be a biomarker of disease activity in AAV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To assess clinical and B cell biomarkers to predict relapse after rituximab in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) using retreatment on clinical relapse strategy. METHODS: 35 patients with AAV received treatment with 2×1000 mg rituximab, repeated on clinical relapse (up to 5 cycles). Disease activity was assessed by Birmingham Vasculitis Activity Score (BVAS) and peripheral B cell subsets using highly sensitive flow cytometry (HSFC) as previously described; both performed at baseline and every 3 months. RESULTS: Response rates were high: >83%, with median time-to-relapse of 82 weeks for cycle 1 (C1) and >54 weeks for all cycles. Prior to rituximab, AAV was characterised by naïve B-lymphopenia compared to healthy controls. This dysregulation was more marked in patients with raised C-reactive protein (CRP) (p<0.05). In C1, no clinical feature predicted relapse. However, repopulation of naïve B cell at 6 months was associated with a reduced risk of relapse (HR: 0.326, 95% 0.114 to 0.930, p=0.036). Relapse rates at 12 and 18 months were 0% and 14% with naïve repopulation at 6 months, and 31% and 54% without naïve repopulation. CONCLUSIONS: Responses to B cell depletion therapy are long-lasting and relapse post-treatment may be predicted by absence of naïve B cell repopulation at 6 months. Naïve B-lymphopenia may be a biomarker of disease activity in AAV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
B cells; Cyclophosphamide; DMARDs (biologic); Granulomatosis with polyangiitis; Systemic vasculitis
Authors: Divi Cornec; Brian F Kabat; John R Mills; Melissa Cheu; Amber M Hummel; Darrell R Schroeder; Matthew D Cascino; Paul Brunetta; David L Murray; Melissa R Snyder; Fernando Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; David R Barnidge; Ulrich Specks Journal: Rheumatology (Oxford) Date: 2018-04-01 Impact factor: 7.580
Authors: Laura S van Dam; Jelle M Oskam; Sylvia W A Kamerling; Eline J Arends; O W Bredewold; Magdalena A Berkowska; Jacques J M van Dongen; Ton J Rabelink; Cees van Kooten; Y K Onno Teng Journal: Front Immunol Date: 2020-12-15 Impact factor: 7.561
Authors: Alvise Berti; Sophie Hillion; Amber M Hummel; Young Min Son; Nedra Chriti; Tobias Peikert; Eva M Carmona; Wayel H Abdulahad; Peter Heeringa; Kristina M Harris; E William St Clair; Paul Brunetta; Fernando C Fervenza; Carol A Langford; Cees Gm Kallenberg; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; John H Stone; Guido Grandi; Jie Sun; Jacques-Olivier Pers; Ulrich Specks; Divi Cornec Journal: JCI Insight Date: 2021-11-22
Authors: Jack Arnold; Edward M Vital; Shouvik Dass; Aamir Aslam; Andy C Rawstron; Sinisa Savic; Paul Emery; Md Yuzaiful Md Yusof Journal: Front Immunol Date: 2022-01-12 Impact factor: 7.561
Authors: Ingeborg M Bajema; Jan A Bruijn; Alina Casian; Maria C Cid; Elena Csernok; Emma van Daalen; Lorraine Harper; Thomas Hauser; Mark A Little; Raashid A Luqmani; Alfred Mahr; Cristina Ponte; Alan Salama; Mårten Segelmark; Kazuo Suzuki; Jan Sznajd; Y K Onno Teng; Augusto Vaglio; Kerstin Westman; David Jayne Journal: Kidney Int Rep Date: 2017-09-21